ArchiMed and CDPQ invest in Corealis Pharma

LYON, MONTRÉAL and LAVAL — Trans-Atlantic private equity healthcare specialist ArchiMed and global investor group Caisse de dépôt et placement du Québec (CDPQ) have invested in Corealis Pharma. The partnership will further expand the drug development services Corealis offers as a Contract Development and Manufacturing Organization to small and medium-sized biotech and pharma companies.

Founded in 2005 and based in Laval, Québec, Canada, Corealis is a CDMO in the Americas involved in the formulation development and manufacture of oral solid dosage pharmaceuticals – tablets, capsules, and granules – during pre-commercialization preclinical and clinical phases.

“ArchiMed and CDPQ understood our strategy and offered an attractive investment thesis,” says Yves Roy, President of Corealis. “Like us, our new investors understand the important potential of this industry and what it takes to get to the next level. As partners we’ll be able to capitalize on market leadership, aggressively expanding scientific strengths in R&D and our best-in-class regulatory-compliant manufacturing processes known as Good Manufacturing Practices or GMP.” Roy and fellow founders Patrick Gosselin and Yves Mouget reportedly remain fully involved in Corealis.

“With Corealis’ expertise, CDPQ’s clout, and our knowledge of the international healthcare landscape, we’ve got the perfect combination to rapidly scale up in a fast-growing industry,” says ArchiMed Partner Robin Filmer-Wilson.

“CDPQ recognizes the extensive expertise of the co-founders and is delighted to take a stake, alongside ArchiMed, in Corealis, a Quebec based pharmaceutical services company that is recognize for its technical abilities here and across North America,” said Kim Thomassin, Executive Vice-President and Head of Québec at CDPQ. “Corealis is a key contributor in Québec’s pharmaceutical sector, an industry with a strong growth outlook.”